|
|
|
 |
Steven U. Walkley
Professor
Pathobiology and treatment of genetic neurological diseases; cerebral
cortical development; ganglioside function in neurons.
Kennedy Center
Room 618
(718) 430-4025
|
|
Pathobiology and Treatment of Lysosomal Disorders
of Brain
The research interests of my laboratory are concerned
with analysis of pathogenic cascades and development
of therapeutic strategies for genetic disorders of the
endosomal-lysosomal system known as neuronal storage
diseases. Disorders include Tay-Sachs, Hurler, Sanfilippo,
Niemann-Pick, Batten, and other related conditions,
all of which are characterized by insidious onset and
progression of neurological dysfunction, including mental
retardation, following an initial period of normal development.
Primary proteins implicated in storage diseases include
not only lysosomal hydrolases but also soluble and membrane-associated
proteins often of unknown function. Animal models of
storage diseases include both spontaneous conditions
in a variety of species and gene knockout models in
mice, both of which are used extensively in our studies.
Neurons affected by storage diseases often display remarkable
features, including growth of ectopic dendrites and
altered synaptic connectivity, formation of axonal defects,
and selective vulnerability to premature death. Our
studies are focused on the link between the primary
protein defect and the abnormal accumulation of substrate
(gangliosides, glycosaminoglycans, cholesterol, and
so forth) and with subsequent induced changes in trafficking
and signaling events within affected neurons. Therapeutic
strategies include attempts to replace missing proteins
through cell-mediated approaches (e.g., bone marrow
transplantation) and to reduce storage pharmacologically
with inhibitors of substrate synthesis (substrate reduction
therapy), both of which have shown promise in specific
types of storage disorders.

Selected Publications
Zhou S., Davidson C., McGlynn R., Stephney G., Dobrenis K, Vanier M.T., Walkley S.U., Endosomal/Lysosomal Processing of Gangliosides Affects Neuronal Cholesterol Sequestration in Niemann-Pick Disease Type C. Am J Pathol June 2, 2011 (Epub ahead of print) PMID:21708114
Davidson, C. D, Ali, N.F., Micsenyi, M.C., Stephney, G., Dobrenis, K., Ory, D.S., Vanier, M.T., and Walkley, S.U., Chronic cyclodextrin administration in Niemann-Pick C disease ameliorates intraneuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE (epubl Sept 11, 2009). PMCID: PMC2736622
Walkley, S.U. and Vanier, M.T. (2009) Secondary Lipid Accumulation in Lysosomal Disease. Biochem Biophys Acta 1793:726-736.
Walkley, S.U. (2009) Lysosomal diseases – Why so complex? J Inherit Met Dis. 32:181-189.
Micsenyi, M.C., Dobrenis, K., Stephney, G., Pickel, J. Vanier, M.T., Slaugenhaupt, S.A., and Walkley, S.U. (2009) Neuropathology of the Mcoln1-/- knockout mouse model of Mucolipidosis IV. J. Neuropath Exp Neurol 68:125-135.
Walkley, S.U. (2007) Pathogenic mechanisms in lysosomal disease: A reappraisal of the role of the lysosome. Acta Paediatrica 96 (s455):26-32.
McGlynn, R., Dobrenis, K., and Walkley, S.U. (2004) Differential subcellular localization of cholesterol, gangliosides and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J. Comp. Neurol. 480:415-426.
Platt, F. and Walkley, S.U., eds., Lysosomal Disorders of the Brain, Oxford University Press, 2004.
|
|